Pamela Holland, PhD
Pam Holland, PhD, oversees biology and immunology at Surface Oncology. Pam is an experienced cancer biologist with a proven track record of successfully managing and bringing forward pre-clinical stage cancer therapeutics into clinical development. Prior to joining Surface, Pam held roles of increasing responsibility in oncology research and the Therapeutic Innovation Unit at Amgen. Pam worked extensively on TNF-receptor superfamily members including death-receptor agonists. She was the global research lead for dulanermin (recombinant Apo2L/TRAIL) in collaboration with Genentech and also supported the development of conatumumab (DR5 agonist antibody) and birinapant, a small molecule IAP antagonist, in collaboration with TetraLogic. Members of her team were instrumental in the development of multiple discovery programs for cancer immunotherapy.
Pam received her Bachelor of Arts in Animal Physiology from the University of California, San Diego and received her PhD in Biochemistry from the University of Washington/Fred Hutchinson Cancer Research Center in the Lab of Dr. Jonathan Cooper. Prior to entering graduate school Pam worked at Cetus Corporation in Emeryville, CA where she was a key contributor to the development of TaqManTM. She is a co-inventor on all TaqMan patents and was the lead author on the first publication describing TaqMan in 1991.